Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALLZITAL vs PHRENILIN FORTE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Allzital contains phenobarbital, a barbiturate that enhances GABA-A receptor activity by increasing the duration of chloride ion channel opening, leading to neuronal hyperpolarization and inhibition of neurotransmission.
Butalbital: barbiturate that enhances GABA-A receptor activity, causing CNS depression. Acetaminophen: analgesic and antipyretic via COX inhibition and central action. Caffeine: adenosine receptor antagonist, CNS stimulant.
Sedation,Short-term treatment of insomnia,Management of seizure disorders (generalized tonic-clonic and partial seizures),Preoperative anxiety
Tension-type headache
5-10 mg orally every 4-6 hours as needed for pain; not to exceed 40 mg per day.
1 capsule (butalbital 50 mg, acetaminophen 325 mg, caffeine 40 mg) orally every 4 hours as needed; maximum 6 capsules per day.
Terminal elimination half-life is 4-6 hours in healthy adults; prolonged to 8-12 hours in renal impairment.
Butalbital: 35-50 hours (long-acting barbiturate). Acetaminophen: 2-3 hours (therapeutic doses); prolonged in overdose. Caffeine: 3-7 hours (average 5 hours); prolonged in liver disease.
Primarily hepatic via CYP2C9, CYP2C19, and glucuronidation; metabolized to inactive metabolites (e.g., p-hydroxyphenobarbital) that are excreted renally.
Butalbital: primarily hepatic via CYP2C19 and CYP2C9. Acetaminophen: hepatic via glucuronidation (UGT1A1, UGT1A9, UGT2B15), sulfation, and CYP2E1 (minor). Caffeine: hepatic via CYP1A2.
Renal: 70% as unchanged drug; biliary/fecal: 20% as metabolites; 10% other.
Butalbital: ~60-70% renal as unchanged drug and metabolites. Acetaminophen: ~85% renal as sulfate and glucuronide conjugates (2-4% unchanged). Caffeine: ~1% renal unchanged; major metabolites are paraxanthine, theobromine, and theophylline eliminated renally.
92% bound to albumin and alpha-1-acid glycoprotein.
Butalbital: ~30% bound to plasma proteins. Acetaminophen: <5% bound at therapeutic levels. Caffeine: ~35% bound to albumin.
2.5-3.5 L/kg; large Vd indicates extensive tissue distribution.
Butalbital: ~0.8 L/kg (widely distributed). Acetaminophen: ~1 L/kg. Caffeine: ~0.6 L/kg.
Oral: 85-90% due to first-pass metabolism; intravenous: 100%.
Oral bioavailability: Butalbital 90% (well absorbed); Acetaminophen 85-95%; Caffeine 99% (essentially complete).
GFR 30-50 m L/min: 50% dose reduction; GFR <30 m L/min: avoid use.
Not formally established. Acetaminophen component: avoid in severe renal impairment (Cr Cl <10 m L/min) due to accumulation of metabolites; adjust dosing interval to every 6 hours for Cr Cl 10-50 m L/min.
Child-Pugh Class B: 50% dose reduction; Child-Pugh Class C: avoid use.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B): reduce dose to 1 capsule every 6 hours and monitor for hepatotoxicity.
0.1-0.2 mg/kg orally every 4-6 hours as needed; maximum single dose 5 mg; not to exceed 20 mg per day.
Not recommended for pediatric patients due to risk of butalbital dependence and acetaminophen hepatotoxicity. Alternative agents preferred.
Initiate at 2.5 mg orally every 6 hours; titrate cautiously due to increased sensitivity and risk of respiratory depression.
Initiate at 1 capsule every 6 hours; maximum 4 capsules daily. Renal and hepatic function should be monitored, and dose adjusted accordingly.
Risk of respiratory depression, particularly with rapid IV administration or excessive doses; co-administration with CNS depressants (e.g., opioids, alcohol) may exacerbate this effect. Use in pregnancy may cause fetal harm (teratogenic effects).
Acetaminophen may cause severe hepatic injury, including acute liver failure, sometimes resulting in liver transplant or death. Butalbital is habit forming and may be abused; limit use to intermittent treatment.
Respiratory depression, CNS depression, dependence and withdrawal (taper gradually), paradoxical excitation (especially in elderly), use in hepatic or renal impairment, drug interactions with warfarin, oral contraceptives, and corticosteroids.
Hepatotoxicity with acetaminophen overdose; avoid exceeding 4 g/day. Risk of dependence, abuse, and withdrawal with butalbital. CNS depression; avoid alcohol and other sedatives. Renal impairment, hepatic impairment.
Hypersensitivity to barbiturates, severe respiratory insufficiency, history of porphyria, severe hepatic impairment, pregnancy (especially first trimester).
Hypersensitivity to any component; porphyria; severe hepatic impairment; concomitant MAO inhibitor use (or within 14 days)
Avoid excessive alcohol consumption; may increase hepatotoxicity. No significant food interactions. Take with or without food; food may reduce GI upset.
Avoid alcohol and caffeine-containing foods/drinks (e.g., coffee, tea, cola, chocolate) as they may increase side effects like jitteriness or insomnia. Grapefruit juice may alter caffeine metabolism; consider avoiding. No significant food interactions with acetaminophen or butalbital.
Allzital (butalbital/acetaminophen/caffeine) is category C. First trimester: risk of neural tube defects increased with barbiturate exposure; avoid. Second/third trimester: barbiturate use may lead to neonatal withdrawal and coagulation defects due to vitamin K deficiency; use only if benefit outweighs risk.
First trimester: Butalbital (barbiturate) associated with oral clefts, neural tube defects; acetaminophen generally safe, but high doses may cause oxidative stress. Second/third trimester: Butalbital may cause fetal dependence and withdrawal; acetaminophen safe at therapeutic doses. Avoid in pregnancy unless benefit outweighs risk.
Butalbital and acetaminophen are excreted into breast milk in low amounts. Caffeine also enters milk. M/P ratio not established for butalbital. Use caution; monitor infant for sedation, poor feeding. American Academy of Pediatrics considers butalbital compatible with breastfeeding but avoid prolonged use.
Acetaminophen: minimal excretion, M/P ratio ~0.9, considered compatible. Butalbital: excreted in breast milk, M/P ratio ~0.6, may cause infant drowsiness or withdrawal; caution advised. Caffeine: M/P ratio ~0.5-0.8, generally safe in moderate amounts.
No specific dose adjustments established for pregnancy. Pharmacokinetic changes (increased volume of distribution, hepatic metabolism) may reduce butalbital levels; clinical efficacy not well studied. Use lowest effective dose shortest duration. Acetaminophen doses remain standard (<4 g/day). Avoid caffeine >300 mg/day.
Increased renal clearance and volume of distribution in pregnancy may reduce acetaminophen and caffeine levels; no standard dose adjustment recommended. Butalbital: increased clearance due to hepatic enzyme induction and increased Vd; monitor for reduced efficacy; adjust dose based on clinical response. Avoid supratherapeutic doses.
ALLZITAL is a combination analgesic containing acetaminophen and tramadol. Monitor for serotonin syndrome when used with other serotonergic drugs. Avoid in patients with severe hepatic impairment or acute alcohol intoxication. Maximum daily acetaminophen dose is 4000 mg; reduce in hepatic risk. Tramadol may lower seizure threshold; use cautiously in epilepsy. Not recommended in breastfeeding due to tramadol excretion. Adjust dose in renal impairment (Cr Cl <30 m L/min: extended interval). Discontinue gradually to avoid withdrawal.
Phrenilin Forte is a combination of butalbital, acetaminophen, and caffeine used for tension-type headaches. Butalbital is a barbiturate with high abuse potential; limit to short-term use. Acetaminophen hepatotoxicity risk increases with chronic alcohol use. Caffeine may exacerbate anxiety or insomnia. Monitor for signs of dependence or withdrawal. Avoid in patients with porphyria or severe hepatic impairment.
Do not exceed 8 tablets per day due to acetaminophen liver risk.,Avoid alcohol and other acetaminophen-containing products.,May cause dizziness or drowsiness; avoid driving until effect known.,Report signs of serotonin syndrome (agitation, hallucinations, rapid heart rate).,Do not stop suddenly; taper to prevent withdrawal symptoms.,Store at room temperature away from moisture.,Use only as prescribed; risk of dependence with tramadol.
Take only as prescribed; do not exceed recommended dose due to risk of liver damage from acetaminophen.,Avoid alcohol while taking this medication to prevent liver toxicity.,This medication may cause drowsiness or dizziness; do not drive or operate machinery until you know how it affects you.,Do not use with other products containing acetaminophen to avoid overdose.,If you have a history of substance abuse, inform your doctor; this drug can be habit-forming.,Notify your doctor if you experience signs of liver problems (e.g., yellowing of skin/eyes, dark urine) or symptoms of withdrawal (e.g., anxiety, insomnia, tremors).,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALLZITAL vs PHRENILIN FORTE, answered by our medical review team.
ALLZITAL is a Barbiturate Analgesic Combination that works by Allzital contains phenobarbital, a barbiturate that enhances GABA-A receptor activity by increasing the duration of chloride ion channel opening, leading to neuronal hyperpolarization and inhibition of neurotransmission.. PHRENILIN FORTE is a Barbiturate Combination Analgesic that works by Butalbital: barbiturate that enhances GABA-A receptor activity, causing CNS depression. Acetaminophen: analgesic and antipyretic via COX inhibition and central action. Caffeine: adenosine receptor antagonist, CNS stimulant.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALLZITAL and PHRENILIN FORTE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALLZITAL is: 5-10 mg orally every 4-6 hours as needed for pain; not to exceed 40 mg per day.. The standard adult dose of PHRENILIN FORTE is: 1 capsule (butalbital 50 mg, acetaminophen 325 mg, caffeine 40 mg) orally every 4 hours as needed; maximum 6 capsules per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALLZITAL and PHRENILIN FORTE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALLZITAL is classified as Category C. Allzital (butalbital/acetaminophen/caffeine) is category C. First trimester: risk of neural tube defects increased with barbiturate exposure; avoid. Second/third trimester: barbitu. PHRENILIN FORTE is classified as Category C. First trimester: Butalbital (barbiturate) associated with oral clefts, neural tube defects; acetaminophen generally safe, but high doses may cause oxidative stress. Second/third tr. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.